Next-Generation Sequencing-Based Testing Among Patients With Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States: Predictive Modeling Using Machine Learning Methods.

Journal: JMIR cancer
Published Date:

Abstract

BACKGROUND: Next-generation sequencing (NGS) has become a cornerstone of treatment for lung cancer and is recommended in current treatment guidelines for patients with advanced or metastatic disease.

Authors

  • Alan James Michael Brnabic
    Eli Lilly and Company, Sydney, Australia.
  • Ilya Lipkovich
    Eli Lilly and Company Indianapolis Indiana USA.
  • Zbigniew Kadziola
    Eli Lilly and Company, Indianapolis, IN, United States.
  • Dan He
    IBM T.J. Watson Research, Yorktown Heights, NY, USA.
  • Peter M Krein
    Eli Lilly and Company, Indianapolis, IN, United States.
  • Lisa M Hess
    Eli Lilly and Company, Indianapolis, IN, USA. hess_lisa_m@lilly.com.